Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
The OncLive Insider app is live!
CME Opportunities
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
ASH Annual Meeting - Episode 2
2014 ASH Annual Meeting
December 11, 2014
EP. 1: RESPONSE Trial Validates Ruxolitinib in Polycythemia Vera
Now Viewing
EP. 2: 2014 ASH Annual Meeting
EP. 3: Two Experts Discuss JAK Inhibition in Polycythemia Vera
EP. 4: Dr Topp on the Efficacy of Glofitamab Plus R-CHOP in Previously Untreated DLBCL
Related Content:
ASH Annual Meeting
Myeloproliferative Neoplasms
Multiple Myeloma
Hematologic Oncology
Epcoritamab Plus R-ICE Yields High CR Rates and Improves Transplant Eligibility in R/R DLBCL
Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL
Consolidation Blinatumomab Improves Efficacy Vs Chemo in Newly Diagnosed BCR::ABL1– B ALL
x